# Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations

Source: https://onco.cc/trials/nct06998940/  
OnCo record `nct06998940` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of fluorouracil (5-FU), gemcitabine, fOLFIRI (5-FU, leucovorin, irinotecan), fLOT (5-FU, leucovorin, oxaliplatin, docetaxel) and other drugs in pancreatic cancer, run by SWOG Cancer Research Network, now recruiting.

## Summary

Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations is a phase 3, randomised interventional study registered as NCT06998940 by SWOG Cancer Research Network, with a registry enrolment figure of 94 participants, started 2026-05-13 and due to reach its primary completion in 2029-12-31. Interventions recorded: Biospecimen Collection; Computed Tomography; Fluorouracil; Gemcitabine; Irinotecan; Irinotecan Sucrosofate; Leucovorin; Nab-paclitaxel; Panitumumab; Questionnaire Administration. Conditions listed: Locally Advanced Pancreatic Adenocarcinoma; Metastatic Pancreatic Adenocarcinoma; Stage III Pancreatic Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8; Unresectable Pancreatic Adenocarcinoma. Primary outcome: Overall survival (OS). Pancreatic eligibility wording from the registry: "* Participants must have a histologically or cytologically confirmed diagnosis of ductal adenocarcinoma of the pancreas". Sites: United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; pancreatic-deep-dive
- Registry id: NCT06998940
- Phase: 3
- Setting: Randomized Phase III Study of Second-Line Chemotherapy With or Without Panitumumab for KRAS Wild Type, Locally Advanced or Metastatic Pancreatic Adenocarcinoma
- Sponsor: SWOG Cancer Research Network
- Enrolled: 94

## Sources

- ClinicalTrials.gov NCT06998940: https://clinicaltrials.gov/study/NCT06998940

## Connected records

- cancers: [KRAS wild-type pancreatic ductal adenocarcinoma](https://onco.cc/cancers/kras-wild-type-pdac/), [Locally advanced unresectable pancreatic ductal adenocarcinoma](https://onco.cc/cancers/locally-advanced-pdac/), [Metastatic pancreatic ductal adenocarcinoma](https://onco.cc/cancers/metastatic-pdac/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/)
- drugs: [FLOT (5-FU, leucovorin, oxaliplatin, docetaxel)](https://onco.cc/drugs/flot/), [Fluorouracil (5-FU)](https://onco.cc/drugs/fluorouracil/), [FOLFIRI (5-FU, leucovorin, irinotecan)](https://onco.cc/drugs/folfiri/), [Gemcitabine](https://onco.cc/drugs/gemcitabine/), [Nab-paclitaxel](https://onco.cc/drugs/nab-paclitaxel/), [Panitumumab](https://onco.cc/drugs/panitumumab/)
- terms: [Pancreatic cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/pancreatic-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06998940.json